FI3698791T3 - Intranasaalinen koostumus, joka käsittää betahistiiniä - Google Patents
Intranasaalinen koostumus, joka käsittää betahistiiniä Download PDFInfo
- Publication number
- FI3698791T3 FI3698791T3 FIEP20170448.3T FI20170448T FI3698791T3 FI 3698791 T3 FI3698791 T3 FI 3698791T3 FI 20170448 T FI20170448 T FI 20170448T FI 3698791 T3 FI3698791 T3 FI 3698791T3
- Authority
- FI
- Finland
- Prior art keywords
- betahistine
- pharmaceutical composition
- dose
- composition according
- dihydrochloride
- Prior art date
Links
- UUQMNUMQCIQDMZ-UHFFFAOYSA-N betahistine Chemical compound CNCCC1=CC=CC=N1 UUQMNUMQCIQDMZ-UHFFFAOYSA-N 0.000 title claims 24
- 229960004536 betahistine Drugs 0.000 title claims 24
- 239000000203 mixture Substances 0.000 title claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 9
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 208000027601 Inner ear disease Diseases 0.000 claims 4
- 235000011187 glycerol Nutrition 0.000 claims 4
- 235000013772 propylene glycol Nutrition 0.000 claims 4
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 3
- 208000021017 Weight Gain Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 230000003020 moisturizing effect Effects 0.000 claims 3
- 208000027491 vestibular disease Diseases 0.000 claims 3
- 230000004584 weight gain Effects 0.000 claims 3
- 235000019786 weight gain Nutrition 0.000 claims 3
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 claims 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims 2
- 235000013773 glyceryl triacetate Nutrition 0.000 claims 2
- 239000001087 glyceryl triacetate Substances 0.000 claims 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 2
- 229960002622 triacetin Drugs 0.000 claims 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims 1
- 208000026845 Cochlear disease Diseases 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- 206010011878 Deafness Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 229920000084 Gum arabic Polymers 0.000 claims 1
- 102000000543 Histamine Receptors Human genes 0.000 claims 1
- 108010002059 Histamine Receptors Proteins 0.000 claims 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- 239000005913 Maltodextrin Substances 0.000 claims 1
- 229920002774 Maltodextrin Polymers 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 208000027530 Meniere disease Diseases 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 229920001100 Polydextrose Polymers 0.000 claims 1
- 239000004698 Polyethylene Substances 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 1
- 241000978776 Senegalia senegal Species 0.000 claims 1
- 229920002125 Sokalan® Polymers 0.000 claims 1
- 208000009205 Tinnitus Diseases 0.000 claims 1
- 229920001615 Tragacanth Polymers 0.000 claims 1
- 208000012886 Vertigo Diseases 0.000 claims 1
- 235000010489 acacia gum Nutrition 0.000 claims 1
- 239000000205 acacia gum Substances 0.000 claims 1
- 235000010443 alginic acid Nutrition 0.000 claims 1
- 229920000615 alginic acid Polymers 0.000 claims 1
- 230000000561 anti-psychotic effect Effects 0.000 claims 1
- 239000000164 antipsychotic agent Substances 0.000 claims 1
- 239000000305 astragalus gummifer gum Substances 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- 239000008121 dextrose Substances 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229960001031 glucose Drugs 0.000 claims 1
- 229960005150 glycerol Drugs 0.000 claims 1
- 231100000888 hearing loss Toxicity 0.000 claims 1
- 230000010370 hearing loss Effects 0.000 claims 1
- 208000016354 hearing loss disease Diseases 0.000 claims 1
- 229940051250 hexylene glycol Drugs 0.000 claims 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- 229940035034 maltodextrin Drugs 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 229960001855 mannitol Drugs 0.000 claims 1
- 229920000609 methyl cellulose Polymers 0.000 claims 1
- 239000001923 methylcellulose Substances 0.000 claims 1
- 235000010981 methylcellulose Nutrition 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims 1
- 229960005017 olanzapine Drugs 0.000 claims 1
- 239000001814 pectin Substances 0.000 claims 1
- 235000010987 pectin Nutrition 0.000 claims 1
- 229920001277 pectin Polymers 0.000 claims 1
- 239000001259 polydextrose Substances 0.000 claims 1
- 235000013856 polydextrose Nutrition 0.000 claims 1
- 229940035035 polydextrose Drugs 0.000 claims 1
- -1 polyethylene Polymers 0.000 claims 1
- 229920000573 polyethylene Polymers 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 239000008109 sodium starch glycolate Substances 0.000 claims 1
- 229940079832 sodium starch glycolate Drugs 0.000 claims 1
- 229920003109 sodium starch glycolate Polymers 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 229960002920 sorbitol Drugs 0.000 claims 1
- 235000010356 sorbitol Nutrition 0.000 claims 1
- 231100000886 tinnitus Toxicity 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Otolaryngology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762453931P | 2017-02-02 | 2017-02-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3698791T3 true FI3698791T3 (fi) | 2024-01-11 |
Family
ID=61187302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP20170448.3T FI3698791T3 (fi) | 2017-02-02 | 2018-02-02 | Intranasaalinen koostumus, joka käsittää betahistiiniä |
Country Status (33)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018170532A1 (en) * | 2017-03-22 | 2018-09-27 | Franz, Lilian Ann | Treatment method |
| US20230338279A1 (en) * | 2020-04-14 | 2023-10-26 | Glaxosmithkline Consumer Healthcare Holdings (Us) Llc | Nasal spray formulation with moisturizing benefits |
| JP2023523410A (ja) * | 2020-04-22 | 2023-06-05 | サノタイズ リサーチ アンド ディベロップメント コープ． | 上気道感染症を治療するための組成物および方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2397840B1 (enExample) | 1977-07-22 | 1981-03-20 | Cherqui Jean | |
| IT1229237B (it) * | 1989-05-08 | 1991-07-26 | Prodotti Formenti | Sali di (2-(piridil)etil) metilammina |
| JPH03287535A (ja) * | 1990-03-31 | 1991-12-18 | Bairon Boeki Kk | プラノプロフェン水溶液 |
| JP3203056B2 (ja) * | 1992-08-13 | 2001-08-27 | 株式会社ティ・ティ・エス技術研究所 | メシル酸ベタヒスチンの経皮吸収製剤用組成物および経皮吸収製剤 |
| US5897858A (en) * | 1994-02-03 | 1999-04-27 | Schering-Plough Healthcare Products, Inc. | Nasal spray compositions exhibiting increased retention in the nasal cavity |
| JPH10139667A (ja) * | 1996-11-15 | 1998-05-26 | Yoshitomi Pharmaceut Ind Ltd | 水性液剤 |
| CA2446904A1 (en) | 2001-05-24 | 2003-04-03 | Alexza Molecular Delivery Corporation | Delivery of drug esters through an inhalation route |
| US7090830B2 (en) | 2001-05-24 | 2006-08-15 | Alexza Pharmaceuticals, Inc. | Drug condensation aerosols and kits |
| JP3555598B2 (ja) | 2001-06-27 | 2004-08-18 | 株式会社村田製作所 | 積層型インダクタ |
| JP2004196676A (ja) * | 2002-12-16 | 2004-07-15 | Rohto Pharmaceut Co Ltd | 点鼻剤 |
| JP4733333B2 (ja) * | 2002-12-26 | 2011-07-27 | ライオン株式会社 | 点鼻剤又は洗鼻剤 |
| ES2258694T3 (es) | 2003-11-11 | 2006-09-01 | Mattern, Udo | Sistema de administracion de liberacion controlada de hormonas sexuales para aplicaciones nasales. |
| US7728015B2 (en) * | 2004-04-22 | 2010-06-01 | Mor Research Applications Ltd. | Compositions for weight management |
| WO2005101979A2 (en) | 2004-04-22 | 2005-11-03 | Mor Research Applications Ltd. | Method of food intake management |
| AU2006202950A1 (en) * | 2004-04-22 | 2006-10-19 | Mor Research Applications Ltd. | Methods and Compositions for Weight Management |
| US20060046962A1 (en) | 2004-08-25 | 2006-03-02 | Aegis Therapeutics Llc | Absorption enhancers for drug administration |
| EP1789075A4 (en) | 2004-08-25 | 2009-07-01 | Uab Research Foundation | ABSORPTION ENHANCER FOR DRUG ADMINISTRATION |
| US20070111964A1 (en) * | 2005-08-17 | 2007-05-17 | Fleming And Company, Pharmaceuticals | Vitamin B12 nasal spray and method of use |
| WO2007076140A2 (en) * | 2005-12-23 | 2007-07-05 | University Of Cincinnati | Treatment methods employing histamine h3 receptor antagonists, including betahistine |
| US8242148B2 (en) * | 2005-12-23 | 2012-08-14 | Nelson Erik B | Treatment methods employing histamine H3 receptor antagonists, including betahistine |
| US20080066739A1 (en) | 2006-09-20 | 2008-03-20 | Lemahieu Edward | Methods and systems of delivering medication via inhalation |
| MX2010006932A (es) * | 2007-12-21 | 2010-10-05 | Schering Plough Healthcare | Aumento de la fotoestabilizacion de la oximetazolina. |
| EP2278999B1 (en) * | 2008-04-21 | 2025-01-29 | Dompé farmaceutici S.p.A. | Auris formulations for treating otic diseases and conditions |
| US8642631B2 (en) * | 2008-05-27 | 2014-02-04 | University Of Melbourne | Methods of treating mammals with eustachian tube dysfunctions |
| CN102216257B (zh) * | 2008-10-08 | 2015-11-25 | 凯飞药业公司 | Gaba偶联物及其使用方法 |
| SMT202000576T1 (it) * | 2014-10-03 | 2020-11-10 | Lachesis Biosciences Ltd | Composizioni intranasali per il trattamento di malattie e disturbi neurologici e neurodegenerativi |
-
2018
- 2018-02-02 AR ARP180100254A patent/AR111699A1/es not_active Application Discontinuation
- 2018-02-02 EP EP20170448.3A patent/EP3698791B1/en active Active
- 2018-02-02 NZ NZ755931A patent/NZ755931A/en unknown
- 2018-02-02 MX MX2019008961A patent/MX381932B/es unknown
- 2018-02-02 PL PL20170448.3T patent/PL3698791T3/pl unknown
- 2018-02-02 PT PT201704483T patent/PT3698791T/pt unknown
- 2018-02-02 RS RS20240022A patent/RS65099B1/sr unknown
- 2018-02-02 CN CN202410176958.XA patent/CN118356397A/zh active Pending
- 2018-02-02 HU HUE20170448A patent/HUE065336T2/hu unknown
- 2018-02-02 DK DK18703749.4T patent/DK3474850T3/da active
- 2018-02-02 SI SI201831043T patent/SI3698791T1/sl unknown
- 2018-02-02 PT PT187037494T patent/PT3474850T/pt unknown
- 2018-02-02 WO PCT/EP2018/052695 patent/WO2018141922A1/en not_active Ceased
- 2018-02-02 EP EP18703749.4A patent/EP3474850B1/en active Active
- 2018-02-02 PL PL18703749T patent/PL3474850T3/pl unknown
- 2018-02-02 LT LTEP20170448.3T patent/LT3698791T/lt unknown
- 2018-02-02 CA CA3051725A patent/CA3051725A1/en active Pending
- 2018-02-02 MA MA46778A patent/MA46778B1/fr unknown
- 2018-02-02 MY MYPI2019004366A patent/MY196333A/en unknown
- 2018-02-02 LT LTEP18703749.4T patent/LT3474850T/lt unknown
- 2018-02-02 IL IL268353A patent/IL268353B2/en unknown
- 2018-02-02 TN TNP/2019/000220A patent/TN2019000220A1/en unknown
- 2018-02-02 ES ES18703749T patent/ES2807798T3/es active Active
- 2018-02-02 AU AU2018216970A patent/AU2018216970B2/en active Active
- 2018-02-02 SI SI201830082T patent/SI3474850T1/sl unknown
- 2018-02-02 JP JP2019541717A patent/JP7714323B2/ja active Active
- 2018-02-02 TW TW107103800A patent/TWI760429B/zh active
- 2018-02-02 CN CN201880017726.2A patent/CN110418643A/zh active Pending
- 2018-02-02 KR KR1020197025622A patent/KR102653545B1/ko active Active
- 2018-02-02 ES ES20170448T patent/ES2969301T3/es active Active
- 2018-02-02 US US15/887,388 patent/US10456386B2/en active Active
- 2018-02-02 HR HRP20201137TT patent/HRP20201137T1/hr unknown
- 2018-02-02 EA EA201991817A patent/EA201991817A1/ru unknown
- 2018-02-02 FI FIEP20170448.3T patent/FI3698791T3/fi active
- 2018-02-02 HU HUE18703749A patent/HUE050829T2/hu unknown
- 2018-02-02 RS RS20200851A patent/RS60554B1/sr unknown
- 2018-02-02 PH PH1/2019/501785A patent/PH12019501785B1/en unknown
- 2018-02-02 SG SG11201906980YA patent/SG11201906980YA/en unknown
- 2018-02-02 HR HRP20231706TT patent/HRP20231706T1/hr unknown
- 2018-02-02 DK DK20170448.3T patent/DK3698791T3/da active
-
2019
- 2019-07-26 SA SA519402324A patent/SA519402324B1/ar unknown
- 2019-07-29 ZA ZA2019/04955A patent/ZA201904955B/en unknown
- 2019-07-30 CL CL2019002145A patent/CL2019002145A1/es unknown
- 2019-08-09 CO CONC2019/0008657A patent/CO2019008657A2/es unknown
- 2019-09-13 US US16/570,156 patent/US20200022963A1/en not_active Abandoned
-
2022
- 2022-02-08 JP JP2022017792A patent/JP2022051872A/ja not_active Withdrawn
-
2024
- 2024-01-04 JP JP2024000158A patent/JP2024019731A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8450339B2 (en) | Compositions for treatment of common cold | |
| US5801161A (en) | Pharmaceutical composition for the intranasal administration of hydroxocobalamin | |
| US20130225604A1 (en) | Use of flibanserin for the treatment of pre-menopausal sexual desire disorders | |
| ES2256865T3 (es) | Inhibidores de acetil colina esterasa para tratar y diagnosticar desordenes en la respiracion durante el sueño. | |
| US20150359738A1 (en) | Methods of Anesthetizing Nerve Tissue in the Trigeminal Nerve Pathway and Medical Uses Thereof | |
| JP2009542657A5 (enExample) | ||
| IL174562A0 (en) | Oros push-stick for controlled delivery of active agent | |
| PE20040134A1 (es) | Forma de dosificacion de una vez al dia de pramipexol | |
| WO2009032870A3 (en) | Method to ameliorate oxidative stress and improve working memory via pterostilbene administration | |
| RU2010107843A (ru) | Бупропиона гидробромид и его терапевтические применения | |
| JP2007176958A (ja) | セチリジン及びプソイドエフェドリンを含む錠剤 | |
| FI3698791T3 (fi) | Intranasaalinen koostumus, joka käsittää betahistiiniä | |
| JP4041460B2 (ja) | セチリジン及びプソイドエフェドリンを含む錠剤 | |
| EP4520394A3 (en) | New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases | |
| IL311534A (en) | Methods of treating ocular inflammatory diseases | |
| JP2020506930A5 (enExample) | ||
| RU2017112930A (ru) | Офтальмологические составы для доставки лекарств и защиты переднего отдела глаза | |
| MX2024006270A (es) | Nueva composicion farmaceutica oral y regimen de dosificacion para la terapia de enfermedades pulmonares intersticiales fibrosantes progresivas. | |
| JP2009539893A (ja) | 組合せウェーハ | |
| CN118948739A (zh) | 右美托咪定滴鼻剂或鼻喷剂在助眠药物制备中的应用 | |
| JP2011144111A (ja) | 軸性近視の予防または治療剤 | |
| RU2013105513A (ru) | Производные 1-аминоалкилциклогексана для лечения воспалительных заболеваний кожи | |
| NZ703464A (en) | Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix | |
| CA2368352A1 (en) | Method for treating neurodegeneration | |
| KR101978459B1 (ko) | 조루증 치료용 약학 조성물 및 조루증 치료 방법 |